TY - JOUR T1 - Clopidogrel plus aspirin was inferior to oral anticoagulation for preventing vascular events in atrial fibrillation JF - Evidence Based Medicine JO - Evid Based Med SP - 170 LP - 170 DO - 10.1136/ebm.11.6.170 VL - 11 IS - 6 A2 - , Y1 - 2006/12/01 UR - http://ebm.bmj.com/content/11/6/170.abstract N2 - The ACTIVE Writing Group on behalf of the ACTIVE Investigators; Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903–12.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients with atrial fibrillation (AF), is clopidogrel plus aspirin non-inferior to oral anticoagulation for preventing vascular events? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★☆ Cardiology ★★★★★★☆ Haematology ★★★★★★★ Design: randomised controlled trial (Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events [ACTIVE W]). Allocation: concealed.* Blinding: blinded (outcome assessors and monitoring committee).* Follow up period: median 1.28 years. Setting: 30 clinical centres worldwide. Patients: 6706 patients (mean age 70 y, 66% men) with AF and ⩾1 of the following criteria: age ⩾75 years; receiving treatment for systemic hypertension; previous stroke, transient ischaemic attack, or non-central nervous system (non-CNS) systemic embolus; left ventricular dysfunction with left ventricular ejection fraction <45%; peripheral arterial disease; or age 55–74 years with diabetes mellitus requiring drug therapy … ER -